JP2007530550A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530550A5
JP2007530550A5 JP2007505054A JP2007505054A JP2007530550A5 JP 2007530550 A5 JP2007530550 A5 JP 2007530550A5 JP 2007505054 A JP2007505054 A JP 2007505054A JP 2007505054 A JP2007505054 A JP 2007505054A JP 2007530550 A5 JP2007530550 A5 JP 2007530550A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
alkenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009301 external-priority patent/WO2005097806A1/en
Publication of JP2007530550A publication Critical patent/JP2007530550A/ja
Publication of JP2007530550A5 publication Critical patent/JP2007530550A5/ja
Pending legal-status Critical Current

Links

JP2007505054A 2004-03-26 2005-03-17 異脂肪血症を治療するための化合物および方法 Pending JP2007530550A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22
PCT/US2005/009301 WO2005097806A1 (en) 2004-03-26 2005-03-17 Compounds and methods for treating dyslipidemia

Publications (2)

Publication Number Publication Date
JP2007530550A JP2007530550A (ja) 2007-11-01
JP2007530550A5 true JP2007530550A5 (https=) 2008-04-24

Family

ID=34963426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505054A Pending JP2007530550A (ja) 2004-03-26 2005-03-17 異脂肪血症を治療するための化合物および方法

Country Status (21)

Country Link
US (2) US7470705B2 (https=)
EP (2) EP1735320B1 (https=)
JP (1) JP2007530550A (https=)
KR (1) KR20070007112A (https=)
AT (2) ATE433984T1 (https=)
AU (1) AU2005230915A1 (https=)
BR (1) BRPI0508966A (https=)
CA (1) CA2557010A1 (https=)
CY (1) CY1110398T1 (https=)
DE (2) DE602005008416D1 (https=)
DK (1) DK1732933T3 (https=)
EA (1) EA200601785A1 (https=)
EC (1) ECSP066886A (https=)
ES (2) ES2326326T3 (https=)
IL (1) IL177962A0 (https=)
MA (1) MA28550B1 (https=)
NO (1) NO20064763L (https=)
PL (1) PL1732933T3 (https=)
PT (1) PT1732933E (https=)
SI (1) SI1732933T1 (https=)
WO (2) WO2005097805A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) * 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
AU2005267436A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
EP2231601B1 (en) * 2007-12-12 2014-06-18 Amgen Inc. Glycine transporter-1 inhibitors
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
WO2010130773A2 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
BR112012021448A2 (pt) * 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
LT2566505T (lt) 2010-05-06 2020-02-10 Alphacore Pharma Llc Cholesterilo esterio tiekimas į steroidogeninius audinius
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
ES2683350T3 (es) 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
US20140303198A1 (en) 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) * 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
JP2001511813A (ja) * 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
EP1466904A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical BIARYL CONNECTION AND ITS USE
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
BR0306208A (pt) * 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) * 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Similar Documents

Publication Publication Date Title
JP2007530550A5 (https=)
KR20170122820A (ko) 비정상적 불수의 운동 장애의 치료 방법
AU2011328203B2 (en) 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2799640C (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP7493586B2 (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
US8034826B2 (en) Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors
RU2240322C2 (ru) Производные нафтиридина и содержащая их фармацевтическая композиция
JP2005533868A5 (https=)
KR20010050223A (ko) Ｃｒｆ 길항제 및 관련 조성물의 용도
CN105254557A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
JP2019069966A (ja) Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
WO2017176962A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US7176313B2 (en) Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient
EP1145714A1 (en) Drugs
AU2006261162A1 (en) Naphthyridine compounds
US12544363B2 (en) N-methyl-D-aspartic acid receptor modulators
KR20110021946A (ko) 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도
KR20080083706A (ko) 헤테로이환 아마이드 유도체
CN1043574C (zh) 具有中枢神经系统活性的杂环胺
JPWO1997017970A1 (ja) カイニン酸神経細胞毒性阻害剤及びピリドチアジン誘導体
KR20110010725A (ko) 무스카린성 수용체 길항제 및 β２­아드레날린수용체 효능제를 포함하는 제약 생성물
EP2291383B1 (en) New classes of gabaa/bzr ligands
JP2002542247A (ja) モルフィノイド化合物
TW201726617A (zh) Ｓｉｒｔ１受體的四氫咔唑抑制劑
WO2021039961A1 (ja) 縮環ピラゾール誘導体